Skip to main content
Top
Published in: Annals of Surgical Oncology 1/2016

01-01-2016 | Translational Research and Biomarkers

Intramuscular Transplantation Improves Engraftment Rates for Esophageal Patient-Derived Tumor Xenografts

Authors: Matthew Read, MBBS, David Liu, MBBS, BMedSci, Cuong P. Duong, MBBS, FRACS, PhD, Carleen Cullinane, BSc(Hons), PhD, William K. Murray, MBBS, FRCPA, FRCPath, Christina M. Fennell, BBiomedSc(Hons), Jake Shortt, BMedSc, MBChB, FRACP, FRCPA, PhD, David Westerman, MBBS, FRACP, FRCPA, FFSc, Paul Burton, MBBS, FRACS, PhD, Nicholas J. Clemons, BSc(Hons), PhD, Wayne A. Phillips, BSc(Hons), PhD

Published in: Annals of Surgical Oncology | Issue 1/2016

Login to get access

Abstract

Background

Recently, there has been an increase in the availability of targeted molecular therapies for cancer treatment. The application of these approaches to esophageal cancer, however, has been hampered by the relative lack of appropriate models for preclinical testing. Patient-derived tumor xenograft (PDTX) models are gaining popularity for studying many cancers. Unfortunately, it has proven difficult to generate xenografts from esophageal cancer using these models. The purpose of this study was to improve the engraftment efficiency of esophageal PDTXs.

Methods

Fresh pieces of esophageal tumors obtained from endoscopic biopsies or resected specimens were collected from 23 patients. The tumors were then coated in Matrigel and transplanted in immunocompromised mice subcutaneously (n = 6) and/or using a novel implantation technique whereby the tumor is placed in a dorsal intramuscular pocket (n = 18). They are then monitored for engraftment.

Results

With the novel intramuscular technique, successful engraftment was achieved for all 18 patient tumors. Among these PDTXs, 13 recapitulated the original patient tumors with respect to degree of differentiation, molecular and genetic profiles, and chemotherapeutic response. Lymphomatous transformation was observed in the other five PDTXs. Successful engraftment was achieved for only one of six patient tumors using the classic subcutaneous approach.

Discussion

We achieved a much higher engraftment rate of PDTXs using our novel intramuscular transplant technique than has been reported in other published studies. It is hoped that this advancement will help expedite the development and testing of new therapies for esophageal cancer.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.PubMedCrossRef Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.PubMedCrossRef
2.
go back to reference Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef
3.
go back to reference Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97:142–6.PubMedCrossRef Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97:142–6.PubMedCrossRef
5.
7.
go back to reference Dodbiba L, Teichman J, Fleet A, et al. Primary esophageal and gastro-esophageal junction cancer xenograft models: clinicopathological features and engraftment. Lab Invest. 2013;93:397–407.PubMedCrossRef Dodbiba L, Teichman J, Fleet A, et al. Primary esophageal and gastro-esophageal junction cancer xenograft models: clinicopathological features and engraftment. Lab Invest. 2013;93:397–407.PubMedCrossRef
8.
go back to reference Rumpel CA, Powell SM, Moskaluk CA. Mapping of genetic deletions on the long arm of chromosome 4 in human esophageal adenocarcinomas. Am J Pathol. 1999;154:1329–34.PubMedPubMedCentralCrossRef Rumpel CA, Powell SM, Moskaluk CA. Mapping of genetic deletions on the long arm of chromosome 4 in human esophageal adenocarcinomas. Am J Pathol. 1999;154:1329–34.PubMedPubMedCentralCrossRef
9.
go back to reference Boonstra JJ, van Marion R, Douben HJ, et al. Mapping of homozygous deletions in verified esophageal adenocarcinoma cell lines and xenografts. Genes Chromosomes Cancer. 2012;51:272–82.PubMedCrossRef Boonstra JJ, van Marion R, Douben HJ, et al. Mapping of homozygous deletions in verified esophageal adenocarcinoma cell lines and xenografts. Genes Chromosomes Cancer. 2012;51:272–82.PubMedCrossRef
10.
go back to reference De Both NJ, Wijnhoven BPL, Sleddens HFBM, Tilanus HW, Dinjens WNM. Establishment of cell lines from adenocarcinomas of the esophagus and gastric cardia growing in vivo and in vitro. Virchows Arch. 2001;438:451–6.PubMedCrossRef De Both NJ, Wijnhoven BPL, Sleddens HFBM, Tilanus HW, Dinjens WNM. Establishment of cell lines from adenocarcinomas of the esophagus and gastric cardia growing in vivo and in vitro. Virchows Arch. 2001;438:451–6.PubMedCrossRef
11.
go back to reference El-Rifai W, Harper JC, Cummings OW, Hyytinen ER, Frierson HF Jr, Knuutila S, Powell SM. Consistent genetic alterations in xenografts of proximal stomach and gastro-esophageal junction adenocarcinomas. Cancer Res. 1998;58:34–37.PubMed El-Rifai W, Harper JC, Cummings OW, Hyytinen ER, Frierson HF Jr, Knuutila S, Powell SM. Consistent genetic alterations in xenografts of proximal stomach and gastro-esophageal junction adenocarcinomas. Cancer Res. 1998;58:34–37.PubMed
12.
go back to reference Zhang J, Jiang D, Li X, et al. Establishment and characterization of esophageal squamous cell carcinoma patient-derived xenograft mouse models for preclinical drug discovery. Lab Invest. 2014; 94:917–26.PubMedCrossRef Zhang J, Jiang D, Li X, et al. Establishment and characterization of esophageal squamous cell carcinoma patient-derived xenograft mouse models for preclinical drug discovery. Lab Invest. 2014; 94:917–26.PubMedCrossRef
13.
14.
go back to reference Hidalgo M, Amant F, Biankin AV, et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014;4:998–1013.PubMedPubMedCentralCrossRef Hidalgo M, Amant F, Biankin AV, et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014;4:998–1013.PubMedPubMedCentralCrossRef
15.
go back to reference Taniere P, Borghi-Scoazec G, Saurin JC, et al. Cytokeratin expression in adenocarcinomas of the esophagogastric junction: a comparative study of adenocarcinomas of the distal esophagus and of the proximal stomach. Am J Surg Pathol. 2002;26:1213–21.PubMedCrossRef Taniere P, Borghi-Scoazec G, Saurin JC, et al. Cytokeratin expression in adenocarcinomas of the esophagogastric junction: a comparative study of adenocarcinomas of the distal esophagus and of the proximal stomach. Am J Surg Pathol. 2002;26:1213–21.PubMedCrossRef
16.
go back to reference Clemons NJ, Do H, Fennell C, Deb S, Fellowes A, Dobrovic A, Phillips WA. Characterization of a novel tumorigenic esophageal adenocarcinoma cell line: OANC1. Dig Dis Sci. 2014;59:78–88.PubMedCrossRef Clemons NJ, Do H, Fennell C, Deb S, Fellowes A, Dobrovic A, Phillips WA. Characterization of a novel tumorigenic esophageal adenocarcinoma cell line: OANC1. Dig Dis Sci. 2014;59:78–88.PubMedCrossRef
17.
go back to reference Lieber J, Eicher C, Wenz J, Kirchner B, Warmann SW, Fuchs J, Armeanu-Ebinger S. The BH3 mimetic ABT-737 increases treatment efficiency of paclitaxel against hepatoblastoma. BMC Cancer. 2011;11:362.PubMedPubMedCentralCrossRef Lieber J, Eicher C, Wenz J, Kirchner B, Warmann SW, Fuchs J, Armeanu-Ebinger S. The BH3 mimetic ABT-737 increases treatment efficiency of paclitaxel against hepatoblastoma. BMC Cancer. 2011;11:362.PubMedPubMedCentralCrossRef
18.
go back to reference Wunderlich M, Mizukawa B, Chou F, Sexton C, Shrestha M, Saunthararajah Y, Mulloy JC. AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model. Blood. 2013;121:e90–7.PubMedPubMedCentralCrossRef Wunderlich M, Mizukawa B, Chou F, Sexton C, Shrestha M, Saunthararajah Y, Mulloy JC. AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model. Blood. 2013;121:e90–7.PubMedPubMedCentralCrossRef
19.
go back to reference Johnsson A, Olsson C, Nygren O, Nilsson M, Seiving B, Cavallin-Stahl E. Pharmacokinetics and tissue distribution of cisplatin in nude mice: platinum levels and cisplatin-DNA adducts. Cancer Chemother Pharmacol. 1995;37:23–31.PubMedCrossRef Johnsson A, Olsson C, Nygren O, Nilsson M, Seiving B, Cavallin-Stahl E. Pharmacokinetics and tissue distribution of cisplatin in nude mice: platinum levels and cisplatin-DNA adducts. Cancer Chemother Pharmacol. 1995;37:23–31.PubMedCrossRef
20.
go back to reference Desgranges C, Razaka G, De Clercq E, Herdewijn P, Balzarini J, Drouillet F, Bricaud H. Effect of (E)-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice. Cancer Res. 1986;46:1094–101.PubMed Desgranges C, Razaka G, De Clercq E, Herdewijn P, Balzarini J, Drouillet F, Bricaud H. Effect of (E)-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice. Cancer Res. 1986;46:1094–101.PubMed
21.
go back to reference Israely T, Dafni H, Granot D, Nevo N, Tsafriri A, Neeman M. Vascular remodeling and angiogenesis in ectopic ovarian transplants: a crucial role of pericytes and vascular smooth muscle cells in maintenance of ovarian grafts. Biol Reprod. 2003;68:2055–64.PubMedCrossRef Israely T, Dafni H, Granot D, Nevo N, Tsafriri A, Neeman M. Vascular remodeling and angiogenesis in ectopic ovarian transplants: a crucial role of pericytes and vascular smooth muscle cells in maintenance of ovarian grafts. Biol Reprod. 2003;68:2055–64.PubMedCrossRef
23.
go back to reference John T, Yanagawa N, Kohler D, et al. Characterization of lymphomas developing in immunodeficient mice implanted with primary human non-small cell lung cancer. J Thorac Oncol. 2012;7:1101–8.PubMedCrossRef John T, Yanagawa N, Kohler D, et al. Characterization of lymphomas developing in immunodeficient mice implanted with primary human non-small cell lung cancer. J Thorac Oncol. 2012;7:1101–8.PubMedCrossRef
24.
go back to reference Chen K, Ahmed S, Adeyi O, Dick JE, Ghanekar A. Human solid tumor xenografts in immunodeficient mice are vulnerable to lymphomagenesis associated with Epstein-Barr virus. PLoS One. 2012;7:e39294.PubMedPubMedCentralCrossRef Chen K, Ahmed S, Adeyi O, Dick JE, Ghanekar A. Human solid tumor xenografts in immunodeficient mice are vulnerable to lymphomagenesis associated with Epstein-Barr virus. PLoS One. 2012;7:e39294.PubMedPubMedCentralCrossRef
25.
go back to reference Vockerodt M, Yap LF, Shannon-Lowe C, Curley H, Wei W, Vrzalikova K, Murray PG. The Epstein-Barr virus and the pathogenesis of lymphoma. J Pathol. DOI: 10.1002/path.4459. Vockerodt M, Yap LF, Shannon-Lowe C, Curley H, Wei W, Vrzalikova K, Murray PG. The Epstein-Barr virus and the pathogenesis of lymphoma. J Pathol. DOI: 10.​1002/​path.​4459.
Metadata
Title
Intramuscular Transplantation Improves Engraftment Rates for Esophageal Patient-Derived Tumor Xenografts
Authors
Matthew Read, MBBS
David Liu, MBBS, BMedSci
Cuong P. Duong, MBBS, FRACS, PhD
Carleen Cullinane, BSc(Hons), PhD
William K. Murray, MBBS, FRCPA, FRCPath
Christina M. Fennell, BBiomedSc(Hons)
Jake Shortt, BMedSc, MBChB, FRACP, FRCPA, PhD
David Westerman, MBBS, FRACP, FRCPA, FFSc
Paul Burton, MBBS, FRACS, PhD
Nicholas J. Clemons, BSc(Hons), PhD
Wayne A. Phillips, BSc(Hons), PhD
Publication date
01-01-2016
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 1/2016
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-015-4425-3

Other articles of this Issue 1/2016

Annals of Surgical Oncology 1/2016 Go to the issue